CapitalStars Financial Research Pvt Ltd

CapitalStars

CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Read More

Commodity Market Services

Commodity Market Services

In this service we provide 3-4 intraday calls in MCX with a high level of accuracy. The calls are given in Precious Metals, Base Metals and Energies. You can also avail Free Tips for two days to test our accuracy and if satisfied you can join the services with Capital Stars. Read More

Nifty Market Services

Nifty Future Services

We provide you around 1-2 nifty calls, Bank Nifty Futures, nifty futures tips, sgx nifty tips Daily. You can gain more profit, Get 2 days free trial calls. Read More

Equity Market Services

Equity Market Services

In this service we provide 2-4 intraday stock cash calls in NSE/BSE with a high level of accuracy.You can also avail Free Stock Tips for two days to test our accuracy and if satisfied you can join stock cash services with Capital Stars. Read More

Register now

CapitalStars provides Free Trial in Intraday as well as in Positional Services of Equity, Derivatives, and Commodities and Forex Markets. We provide recommendations in NSE, BSE, MCX, NCDEX, and MCX-SX etc. We render you enough entry and exit time in our calls so clients can easily maximize their profits. Read More

Thursday 21 December 2017

Capitalstars Updates: Cadila Healthcare jumps 2% on USFDA approval for hypertension drug: 21 Dec 2017

Cadila Healthcare

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited (Cadila), received final USFDA approval to market Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg, and 90 mg. This was announced by Cadila to the stock exchanges on December 21, 2017.

Cadila Healthcare is a fully-integrated, pharmaceutical company with strong presence in the formulations and CRAMS businesses globally. Its formulations business spans India, US, Europe and emerging markets (mainly Brazil and South Africa). The company derived 34% and 41% revenues from India and the US, respectively in FY17.

The USFDA has granted final approval for Nifedipine Extended-Release Tablets USP in strengths of 30 mg, 60 mg, and 90 mg. The drug is used to treat hypertension (high blood pressure) and angina (chest pain). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is currently trading at Rs429.95, up by Rs9.95 or 2.37% from its previous closing of Rs420 on the BSE. The scrip opened at Rs418.5 and has touched a high and low of Rs434.3 and Rs418.5 respectively. The current market cap of the company is Rs42997.19 crore.


Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide a free trial to our client.Join our services and trade with us. 

Also, u can visit:-

capitalstars quick payment

Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

2 comments:

  1. PREMIUM FUTURE BUY NSE MFSL CMP AT 488 TARGET 494-500 SL 480.5
    OUR FIRST TGT 494 ALMOST ACHIEVED IN MFSL BUY CALL, ONCE BOOK PARTIAL PROFIT NOW 493.65 AND TRAIL SL AT COST
    free HNI Options Tips

    ReplyDelete
  2. Brilliant desings, I personaly like the one with the slide on the side.
    computer data entry

    ReplyDelete